✦ LIBER ✦
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
✍ Scribed by Ruth Plummer, Paul Lorigan, Neil Steven, Lucy Scott…
- Book ID
- 120775998
- Publisher
- Springer
- Year
- 2013
- Tongue
- English
- Weight
- 286 KB
- Volume
- 71
- Category
- Article
- ISSN
- 0344-5704
No coin nor oath required. For personal study only.